Related Experiment Video
Updated: Jun 9, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
Pietro Paolo Vitiello1,2, Nadia Saoudi González2,3, Alberto Bardelli1,2
1Department of Oncology, University of Torino, Italy.
Abstract:
The discovery of growth factors and their involvement in cancer represents the foundation of precision oncology. The preclinical and clinical development of agents targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) were accompanied by big hype and hopes, though the clinical testing of such agents clashed with intrinsic and acquired resistance, greatly limiting their therapeutic value. However, a better understanding of the biology of the EGFR signaling pathway in CRC, coupled with the development of liquid biopsy methodologies to study cancer evolution in real time, fostered the clinical refinement of anti-EGFR treatment in CRC. Such a workflow, based on the co-evolution of biology knowledge and clinical development, allowed to couple the discovery of relevant therapy resistance mechanisms to the development of strategies to bypass this resistance. A broader application of this paradigm could prove successful and create an effective shortcut between the bench and the bedside for treatment strategies other than targeted therapy.
Insights
Precision oncology, foundational in cancer treatment, faces challenges with epidermal growth factor receptor (EGFR) targeted therapies in colorectal cancer (CRC) due to resistance. Advances in understanding EGFR signaling and liquid biopsies refine treatments by addressing resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Growth factor discovery underpins precision oncology.
- Targeting epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) initially showed promise but faced significant resistance challenges.
- Resistance mechanisms have limited the therapeutic efficacy of anti-EGFR agents in CRC.
Purpose of the Study:
- To explore the evolution of anti-EGFR treatment strategies in colorectal cancer.
- To highlight the role of understanding EGFR signaling pathway biology in overcoming therapeutic resistance.
- To demonstrate how advancements in liquid biopsy facilitate real-time monitoring of cancer evolution and treatment refinement.
Main Methods:
- Preclinical and clinical development of EGFR-targeting agents.
- Investigation of intrinsic and acquired resistance mechanisms.
- Application of liquid biopsy methodologies for real-time cancer evolution tracking.
- Correlation of biological insights with clinical development.
Main Results:
- Initial clinical development of anti-EGFR agents in CRC was hampered by resistance.
- Enhanced understanding of EGFR pathway biology and liquid biopsy technology enabled refinement of anti-EGFR treatments.
- Identification of resistance mechanisms directly informed the development of strategies to overcome them.
Conclusions:
- The co-evolution of biological knowledge and clinical development is crucial for refining targeted therapies.
- Liquid biopsy and a deeper understanding of cancer biology can overcome resistance to therapies like anti-EGFR agents.
- This paradigm of integrating biological insights with clinical strategies can accelerate therapeutic advancements beyond targeted therapy.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...